10x Genomics (TXG) Non-Current Assets (2018 - 2026)

10x Genomics' Non-Current Assets history runs 9 years deep, the most recent figure standing at $346.0 million for Q1 2026.

• In Q1 2026, Non-Current Assets rose 6.91% year-over-year to $346.0 million; the TTM figure through Mar 2026 stood at $1.4 billion (up 3.14% YoY), while the FY2025 annual figure was $356.9 million, up 6.78% from the prior year.
• Non-Current Assets came in at $346.0 million for Q1 2026 at 10x Genomics, down from $356.9 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $412.1 million in Q1 2023 to a low of $305.9 million in Q1 2022.
• A 5-year average of $357.6 million and a median of $355.8 million in 2024 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets soared 52.16% in 2022 and retreated 13.81% in 2024, its largest moves.
• 10x Genomics' Non-Current Assets stood at $393.9 million in 2022, then slipped by 6.3% to $369.1 million in 2023, then fell by 9.45% to $334.2 million in 2024, then gained by 6.78% to $356.9 million in 2025, then dropped by 3.05% to $346.0 million in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $346.0 million, $356.9 million, and $367.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison